

Pierre Marquet

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1291893/pierre-marquet-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

213
papers

6,870
citations

48
h-index

71
g-index

234
ext. papers

8,020
ext. citations

4.3
avg, IF

5.64
L-index

#	Paper	IF	Citations
213	How has the future investment program stimulated research and innovation in health?. <i>Therapie</i> , 2022 , 77, 19-19	3.8	0
212	A Machine Learning Approach to Predict Interdose Vancomycin Exposure.. <i>Pharmaceutical Research</i> , 2022 , 39, 721	4.5	0
211	Noninvasive Diagnosis of Acute Rejection in Renal Transplant Patients Using Mass Spectrometric Analysis of Urine Samples: A Multicenter Diagnostic Phase III Trial.. <i>Transplantation Direct</i> , 2022 , 8, e1316 ²⁻³	6.3	1
210	Integrative Omics Analysis Unravels Microvascular Inflammation-Related Pathways in Kidney Allograft Biopsies. <i>Frontiers in Immunology</i> , 2021 , 12, 738795	8.4	4
209	Immunosuppressant quantification in intravenous microdialysate towards novel quasi-continuous therapeutic drug monitoring in transplanted patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021 , 59, 935-945	5.9	4
208	Mycophenolic Acid Exposure Prediction Using Machine Learning. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 370-379	6.1	5
207	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Therapeutic Drug Monitoring</i> , 2021 , 43, 150-200	3.2	17
206	Towards therapeutic drug monitoring of mycophenolic acid in mucous membrane pemphigoid: A retrospective single-centre study. <i>Fundamental and Clinical Pharmacology</i> , 2021 , 35, 1179-1187	3.1	0
205	Estimation of drug exposure by machine learning based on simulations from published pharmacokinetic models: The example of tacrolimus. <i>Pharmacological Research</i> , 2021 , 167, 105578	10.2	3
204	Thoroughly Validated Bayesian Estimator and Limited Sampling Strategy for Dose Individualization of Ganciclovir and Valganciclovir in Pediatric Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 1449-1462	6.2	3
203	First-Line Toxicological Screening with Fully Automated Extraction. <i>Journal of Analytical Toxicology</i> , 2021 , 45, 252-268	2.9	1
202	Tacrolimus Exposure Prediction Using Machine Learning. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 361-369	6.1	6
201	Clinical Pharmacokinetics and Bayesian Estimators for the Individual Dose Adjustment of a Generic Formulation of Tacrolimus in Adult Kidney Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 611-622	6.2	2
200	A Machine Learning Approach to Estimate the Glomerular Filtration Rate in Intensive Care Unit Patients Based on Plasma Iohexol Concentrations and Covariates. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 223-233	6.2	2
199	Population pharmacokinetics of ganciclovir and valganciclovir in paediatric solid organ and stem cell transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 3105-3114	3.8	3
198	Tacrolimus Bayesian Dose Adjustment in Pediatric Renal Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2021 , 43, 472-480	3.2	1
197	Pharmacokinetics, Pharmacodynamics, and Therapeutic Drug Monitoring of Valganciclovir and Ganciclovir in Transplantation. <i>Clinical Pharmacology and Therapeutics</i> , 2021 ,	6.1	4

196	Population pharmacokinetics and Bayesian estimators for intravenous mycophenolate mofetil in haematopoietic stem cell transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 1550-1559	3.8	4
195	Professor Folke Sjöqvist peacefully passed away on March 30, 2020. <i>European Journal of Clinical Pharmacology</i> , 2020 , 76, 1477-1478	2.8	
194	Effects of Ischemia-Reperfusion on Tubular Cell Membrane Transporters and Consequences in Kidney Transplantation. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	7
193	Adherence profiles in kidney transplant patients: Causes and consequences. <i>Patient Education and Counseling</i> , 2020 , 103, 189-198	3.1	11
192	Toward a robust tool for pharmacokinetic-based personalization of treatment with tacrolimus in solid organ transplantation: A model-based meta-analysis approach. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2793-2823	3.8	12
191	Comparison of Tacrolimus Starting Doses Based on CYP3A5 Phenotype or Genotype in Kidney Transplant Recipients. <i>Progress in Transplantation</i> , 2019 , 29, 300-308	1.1	1
190	The European Association for Clinical Pharmacology and Therapeutics-25 years young and going strong. <i>European Journal of Clinical Pharmacology</i> , 2019 , 75, 743-750	2.8	7
189	The Key Role of Warm and Cold Ischemia in Uterus Transplantation: A Review. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	13
188	Population pharmacokinetic model and Bayesian estimator for 2 tacrolimus formulations in adult liver transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 1740-1750	3.8	11
187	Development and validation of a peripheral blood mRNA assay for the assessment of antibody-mediated kidney allograft rejection: A multicentre, prospective study. <i>EBioMedicine</i> , 2019 , 46, 463-472	8.8	31
186	Metabolic alterations of uterine grafts after extended cold ischemic storage: experimental study in ewes. <i>Molecular Human Reproduction</i> , 2019 , 25, 647-659	4.4	4
185	Pharmacodynamic Monitoring of mTOR Inhibitors. <i>Therapeutic Drug Monitoring</i> , 2019 , 41, 160-167	3.2	5
184	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. <i>Therapeutic Drug Monitoring</i> , 2019 , 41, 261-307	3.2	163
183	Untargeted Screening of Urinary Peptides Using Offline Nano-Liquid Chromatography: MALDI-TOF/TOF Mass Spectrometry. <i>Methods in Molecular Biology</i> , 2018 , 1788, 113-121	1.4	1
182	Pharmacokinetic Therapeutic Drug Monitoring of Advagraf in More Than 500 Adult Renal Transplant Patients, Using an Expert System Online. <i>Therapeutic Drug Monitoring</i> , 2018 , 40, 285-291	3.2	15
181	Endogenous Metabolites-Mediated Communication Between OAT1/OAT3 and OATP1B1 May Explain the Association Between SLCO1B1 SNPs and Methotrexate Toxicity. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 104, 687-698	6.1	20
180	Ischemia/reperfusion-associated tubular cells injury in renal transplantation: Can metabolomics inform about mechanisms and help identify new therapeutic targets?. <i>Pharmacological Research</i> , 2018 , 129, 34-43	10.2	12
179	A donor and recipient candidate gene association study of allograft loss in renal transplant recipients receiving a tacrolimus-based regimen. <i>American Journal of Transplantation</i> , 2018 , 18, 2905-2913	8.7	8

178	A Limited Sampling Strategy to Estimate Exposure of Everolimus in Whole Blood and Peripheral Blood Mononuclear Cells in Renal Transplant Recipients Using Population Pharmacokinetic Modeling and Bayesian Estimators. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 1459-1469	6.2	8
177	Comment on "Population Pharmacokinetics of Mycophenolic Acid: An Update". <i>Clinical Pharmacokinetics</i> , 2018 , 57, 1211-1213	6.2	4
176	Fully automated sample preparation procedure to measure drugs of abuse in plasma by liquid chromatography tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2018 , 410, 5071-5085	4.4	12
175	Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients. <i>Pharmacological Research</i> , 2018 , 129, 84-94	10.2	17
174	Circulating oxysterol metabolites as potential new surrogate markers in patients with hormone receptor-positive breast cancer: Results of the OXYTAM study. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017 , 169, 210-218	5.1	32
173	Population Pharmacokinetics and Bayesian Estimators for Refined Dose Adjustment of a New Tacrolimus Formulation in Kidney and Liver Transplant Patients. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 1491-1498	6.2 ²⁷	27
172	Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure-effect relationship. <i>Pharmacological Research</i> , 2017 , 121, 138-144	10.2	21
171	A Time-Dependent Model Describes Methotrexate Elimination and Supports Dynamic Modification of MRP2/ABCC2 Activity. <i>Therapeutic Drug Monitoring</i> , 2017 , 39, 145-156	3.2	7
170	Uterus tolerance to extended cold ischemic storage after auto-transplantation in ewes. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017 , 214, 162-167	2.4	27
169	Activity of the Calcineurin Pathway in Patients on the Liver Transplantation Waiting List: Factors of Variability and Response to Tacrolimus Inhibition. <i>Clinical Chemistry</i> , 2017 , 63, 1734-1744	5.5	5
168	Evaluation of Experiences with Immunosuppressive Drugs in Transplantation: Validation of the MESI Scale in French. <i>Pharmaceutical Medicine</i> , 2017 , 31, 455-465	2.3	1
167	Common variants in glucuronidation enzymes and membrane transporters as potential risk factors for colorectal cancer: a case control study. <i>BMC Cancer</i> , 2017 , 17, 901	4.8	4
166	Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. <i>Medicine (United States)</i> , 2017 , 96, e6469	1.8	6
165	Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation. <i>Frontiers in Pharmacology</i> , 2017 , 8, 358	5.6	29
164	An adjustable predictive score of graft survival in kidney transplant patients and the levels of risk linked to de novo donor-specific anti-HLA antibodies. <i>PLoS ONE</i> , 2017 , 12, e0180236	3.7	10
163	Overview of accessibility and quality of antiepileptic drugs in Madagascar. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2016 , 41, 134-40	3.2	4
162	Mycophenolic Acid Pharmacokinetics and Relapse in Children with Steroid-Dependent Idiopathic Nephrotic Syndrome. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016 , 11, 1777-1782	6.9	20
161	Influence of Donor and Recipient CYP3A4, CYP3A5, and ABCB1 Genotypes on Clinical Outcomes and Nephrotoxicity in Liver Transplant Recipients. <i>Transplantation</i> , 2016 , 100, 2129-2137	1.8	18

160	Efficiency and Safety of an Early Dose Adjustment of Ribavirin in Patients Infected With Hepatitis C Underexposed to the Drug and Treated With Peginterferon Ribavirin. <i>Therapeutic Drug Monitoring</i> , 2016 , 38, 684-692	3.2	2
159	Advagraf(®) , a once-daily prolonged release tacrolimus formulation, in kidney transplantation: literature review and guidelines from a panel of experts. <i>Transplant International</i> , 2016 , 29, 860-9	3	25
158	Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs. <i>Therapeutic Drug Monitoring</i> , 2016 , 38 Suppl 1, S57-69	3.2	39
157	New challenges and promises in solid organ transplantation pharmacogenetics: the genetic variability of proteins involved in the pharmacodynamics of immunosuppressive drugs. <i>Pharmacogenomics</i> , 2016 , 17, 277-96	2.6	19
156	QuEChERS sample preparation prior to LC-MS/MS determination of opiates, amphetamines, and cocaine metabolites in whole blood. <i>Analytical and Bioanalytical Chemistry</i> , 2016 , 408, 1467-74	4.4	34
155	Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity?. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 484-9	5.1	16
154	A candidate gene approach of the calcineurin pathway to identify variants associated with clinical outcomes in renal transplantation. <i>Pharmacogenomics</i> , 2016 , 17, 375-91	2.6	12
153	Ribavirin: Past, present and future. <i>World Journal of Hepatology</i> , 2016 , 8, 123-30	3.4	35
152	Anti-hepatitis C virus drugs and kidney. <i>World Journal of Hepatology</i> , 2016 , 8, 1343-1353	3.4	12
151	Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation. <i>Therapeutic Drug Monitoring</i> , 2016 , 38 Suppl 1, S1-20	3.2	57
150	Evolution and Determinants of Health-Related Quality-of-Life in Kidney Transplant Patients Over the First 3 Years After Transplantation. <i>Transplantation</i> , 2016 , 100, 640-7	1.8	18
149	In silico pharmacology: Drug membrane partitioning and crossing. <i>Pharmacological Research</i> , 2016 , 111, 471-486	10.2	33
148	Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study. <i>Transplantation</i> , 2016 , 100, 1705-13	1.8	11
147	Establishing Biomarkers in Transplant Medicine: A Critical Review of Current Approaches. <i>Transplantation</i> , 2016 , 100, 2024-38	1.8	49
146	Therapeutic Drug Monitoring of Everolimus: A Consensus Report. <i>Therapeutic Drug Monitoring</i> , 2016 , 38, 143-69	3.2	71
145	Assuring the Proper Analytical Performance of Measurement Procedures for Immunosuppressive Drug Concentrations in Clinical Practice: Recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Immunosuppressive Drug Scientific Committee. <i>Therapeutic Drug Monitoring</i> , 2016 , 38, 170-89	3.2	65
144	Uterus human leucocyte antigen expression in the perspective of transplantation. <i>Journal of Obstetrics and Gynaecology Research</i> , 2016 , 42, 1789-1795	1.9	1
143	Multidrug resistance-associated protein 4 (MRP4) controls ganciclovir intracellular accumulation and contributes to ganciclovir-induced neutropenia in renal transplant patients. <i>Pharmacological Research</i> , 2016 , 111, 501-508	10.2	12

142	Mycophenolic mofetil optimized pharmacokinetic modelling, and exposure-effect associations in adult heart transplant recipients. <i>Pharmacological Research</i> , 2015 , 99, 308-15	10.2	14
141	Liquid chromatography tandem mass spectrometry quantitation of intracellular concentrations of ganciclovir and its phosphorylated forms. <i>Analytical and Bioanalytical Chemistry</i> , 2015 , 407, 3449-56	4.4	7
140	How to handle missed or delayed doses of tacrolimus in renal transplant recipients? A pharmacokinetic investigation. <i>Pharmacological Research</i> , 2015 , 100, 281-7	10.2	12
139	Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients. <i>Pharmacogenomics</i> , 2015 , 16, 1119-34	2.6	26
138	Translational research: precision medicine, personalized medicine, targeted therapies: marketing or science?. <i>Therapie</i> , 2015 , 70, 1-19	3.8	6
137	Impact of Laboratory Practices on Interlaboratory Variability in Therapeutic Drug Monitoring of Immunosuppressive Drugs. <i>Therapeutic Drug Monitoring</i> , 2015 , 37, 718-24	3.2	35
136	HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents. <i>Liver International</i> , 2015 , 35, 2222-7	7.9	49
135	Pelvic magnetic resonance imaging in the ewe: a model for experimental gynecologic research. <i>Journal of Obstetrics and Gynaecology Research</i> , 2014 , 40, 133-8	1.9	2
134	Calcineurin activity assay measurement by liquid chromatography-tandem mass spectrometry in the multiple reaction monitoring mode. <i>Clinical Chemistry</i> , 2014 , 60, 353-60	5.5	14
133	Tacrolimus pharmacodynamics and pharmacogenetics along the calcineurin pathway in human lymphocytes. <i>Clinical Chemistry</i> , 2014 , 60, 1336-45	5.5	15
132	Uterus retrieval process from brain dead donors. <i>Fertility and Sterility</i> , 2014 , 102, 476-82	4.8	50
131	Pharmacokinetics of mycophenolate mofetil in children with lupus and clinical findings in favour of therapeutic drug monitoring. <i>British Journal of Clinical Pharmacology</i> , 2014 , 78, 867-76	3.8	27
130	Pharmacokinetic tools for the dose adjustment of ciclosporin in haematopoietic stem cell transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2014 , 78, 836-46	3.8	13
129	Associations between polymorphisms in target, metabolism, or transport proteins of mycophenolate sodium and therapeutic or adverse effects in kidney transplant patients. <i>Pharmacogenetics and Genomics</i> , 2014 , 24, 256-62	1.9	23
128	Consensus conference on a composite endpoint for clinical trials on immunosuppressive drugs in lung transplantation. <i>Transplantation</i> , 2014 , 98, 1331-8	1.8	4
127	Ciclosporin population pharmacokinetics and Bayesian estimation in thoracic transplant recipients. <i>Clinical Pharmacokinetics</i> , 2013 , 52, 277-88	6.2	13
126	Acylglucuronide in alkaline conditions: migration vs. hydrolysis. <i>Journal of Molecular Modeling</i> , 2013 , 19, 2423-32	2	4
125	Lessons from routine dose adjustment of tacrolimus in renal transplant patients based on global exposure. <i>Therapeutic Drug Monitoring</i> , 2013 , 35, 322-7	3.2	40

124	Involvement of UDP-glucuronosyltransferases UGT1A9 and UGT2B7 in ethanol glucuronidation, and interactions with common drugs of abuse. <i>Drug Metabolism and Disposition</i> , 2013 , 41, 568-74	4	58
123	Effect of CYP3A4*22, POR*28, and PPARA rs4253728 on sirolimus in vitro metabolism and trough concentrations in kidney transplant recipients. <i>Clinical Chemistry</i> , 2013 , 59, 1761-9	5.5	25
122	Calcineurin regulation of cytoskeleton organization: a new paradigm to analyse the effects of calcineurin inhibitors on the kidney. <i>Journal of Cellular and Molecular Medicine</i> , 2012 , 16, 218-27	5.6	12
121	Sirolimus and everolimus intestinal absorption and interaction with calcineurin inhibitors: a differential effect between cyclosporine and tacrolimus. <i>Fundamental and Clinical Pharmacology</i> , 2012 , 26, 463-72	3.1	25
120	Mapping cyclosporine-induced changes in protein secretion by renal cells using stable isotope labeling with amino acids in cell culture (SILAC). <i>Journal of Proteomics</i> , 2012 , 75, 3674-87	3.9	13
119	LC-MS vs. GC-MS, online extraction systems, advantages of technology for drug screening assays. <i>Methods in Molecular Biology</i> , 2012 , 902, 15-27	1.4	16
118	LC-MS/MS screen for xenobiotics and metabolites. <i>Methods in Molecular Biology</i> , 2012 , 902, 129-38	1.4	1
117	Bayesian estimation of mycophenolate mofetil in lung transplantation, using a population pharmacokinetic model developed in kidney and lung transplant recipients. <i>Clinical Pharmacokinetics</i> , 2012 , 51, 29-39	6.2	21
116	Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation. <i>Clinical Pharmacokinetics</i> , 2012 , 51, 175-86	6.2	49
115	Untargeted screening of urinary peptides with liquid chromatography coupled to hybrid linear-ion trap tandem mass spectrometry. <i>Journal of Chromatography A</i> , 2012 , 1259, 138-47	4.5	1
114	Simultaneous evaluation of six human glucuronidation activities in liver microsomes using liquid chromatography-tandem mass spectrometry. <i>Analytical Biochemistry</i> , 2012 , 427, 52-9	3.1	17
113	Association of sirolimus adverse effects with m-TOR, p70S6K or Raptor polymorphisms in kidney transplant recipients. <i>Pharmacogenetics and Genomics</i> , 2012 , 22, 725-32	1.9	21
112	Pharmacological exposure to ribavirin: a key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment. <i>Digestive and Liver Disease</i> , 2011 , 43, 850-5	3.3	13
111	Post-transplant lymphoproliferative disease (PTLD): Pharmacological, virological and other determinants. <i>Pharmacological Research</i> , 2011 , 63, 1-7	10.2	22
110	Inhibition of T-cell activation and proliferation by mycophenolic acid in patients awaiting liver transplantation: PK/PD relationships. <i>Pharmacological Research</i> , 2011 , 63, 432-8	10.2	18
109	Development of a Bayesian estimator for the therapeutic drug monitoring of mycophenolate mofetil in children with idiopathic nephrotic syndrome. <i>Pharmacological Research</i> , 2011 , 63, 423-31	10.2	37
108	Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters. <i>Xenobiotica</i> , 2011 , 41, 752-7	2	21
107	Development and evaluation of a simulation procedure to take into account various assays for the Bayesian dose adjustment of tacrolimus. <i>Therapeutic Drug Monitoring</i> , 2011 , 33, 171-7	3.2	18

106	CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients. <i>Transplantation</i> , 2011 , 91, 652-6	1.8	53
105	Large scale analysis of routine dose adjustments of mycophenolate mofetil based on global exposure in renal transplant patients. <i>Therapeutic Drug Monitoring</i> , 2011 , 33, 285-94	3.2	34
104	Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations--twice daily Prograf and once daily Advagraf. <i>British Journal of Clinical Pharmacology</i> , 2011 , 71, 391-402	3.8	79
103	Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. <i>Transplantation Reviews</i> , 2011 , 25, 47-57	3.3	89
102	The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011 , 7, 731-43	5.5	28
101	Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele. <i>British Journal of Clinical Pharmacology</i> , 2010 , 69, 675-83	3.8	36
100	Falsely elevated whole-blood tacrolimus concentrations in a kidney-transplant patient: potential hazards. <i>Transplant International</i> , 2010 , 23, 227-30	3	27
99	Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 2628-40	5.1	113
98	Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. <i>Drug Metabolism and Disposition</i> , 2010 , 38, 40-5	4	75
97	Counterpoint: Is pharmacokinetic or pharmacodynamic monitoring of calcineurin inhibition therapy necessary?. <i>Clinical Chemistry</i> , 2010 , 56, 736-9	5.5	9
96	A 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits. <i>Nephrology Dialysis Transplantation</i> , 2010 , 25, 3096-106	4.3	22
95	Feasibility of, and critical paths for mycophenolate mofetil Bayesian dose adjustment: pharmacological re-appraisal of a concentration-controlled versus fixed-dose trial in renal transplant recipients. <i>Pharmacological Research</i> , 2010 , 61, 167-74	10.2	12
94	Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation. <i>Clinical Pharmacokinetics</i> , 2010 , 49, 683-92	6.2	71
93	Ribavirin therapeutic drug monitoring: why, when and how?. <i>Fundamental and Clinical Pharmacology</i> , 2010 , 24, 401-6	3.1	7
92	Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil. <i>Pharmacogenetics and Genomics</i> , 2010 , 20, 537-43	1.9	42
91	Cost-effectiveness analysis of individualized mycophenolate mofetil dosing in kidney transplant patients in the APOMYGRE trial. <i>Transplantation</i> , 2010 , 89, 1255-62	1.8	12
90	Screening of pesticides in blood with liquid chromatography-linear ion trap mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2010 , 396, 2235-49	4.4	35
89	ESI-MS-MS library of 1,253 compounds for application in forensic and clinical toxicology. <i>Analytical and Bioanalytical Chemistry</i> , 2010 , 396, 1947	4.4	7

88	Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2047-54		61
87	Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 129-35	3.2	39
86	Stability of ribavirin concentrations depending on the type of blood collection tube and preanalytical conditions. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 237-41	3.2	9
85	Multisite analytical evaluation of the Abbott ARCHITECT cyclosporine assay. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 145-51	3.2	25
84	Effect of mycophenolate acyl-glucuronide on human recombinant type 2 inosine monophosphate dehydrogenase. <i>Clinical Chemistry</i> , 2009 , 55, 986-93	5.5	27
83	General unknown screening procedure for the characterization of human drug metabolites in forensic toxicology: applications and constraints. <i>Journal of Separation Science</i> , 2009 , 32, 3074-83	3.4	40
82	General unknown screening procedure for the characterization of human drug metabolites: Application to loratadine phase I metabolism. <i>Journal of Separation Science</i> , 2009 , 32, 2209-17	3.4	14
81	Enteric-coated mycophenolate sodium in de novo pediatric renal transplant patients. <i>Pediatric Nephrology</i> , 2009 , 24, 395-402	3.2	5
80	Pretransplantation calcineurin activity: towards individualized therapy?. <i>Liver International</i> , 2009 , 29, 1454-6	7.9	2
79	Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation. <i>Clinical Pharmacokinetics</i> , 2009 , 48, 667-75	6.2	26
78	Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I. <i>Clinical Pharmacokinetics</i> , 2009 , 48, 419-62	6.2	39
77	Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part II. <i>Clinical Pharmacokinetics</i> , 2009 , 48, 489-516	6.2	28
76	Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus. <i>Clinical Pharmacokinetics</i> , 2009 , 48, 745-58	6.2	46
75	Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. <i>Clinical Pharmacokinetics</i> , 2009 , 48, 805-16	6.2	103
74	Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. <i>Therapeutic Drug Monitoring</i> , 2009 , 31, 139-52	3.2	347
73	Feasibility of ribavirin therapeutic drug monitoring in hepatitis C. <i>Therapeutic Drug Monitoring</i> , 2009 , 31, 374-81	3.2	15
72	Mycophenolic acid 12-hour area under the curve in de novo liver transplant patients given mycophenolate mofetil at fixed versus concentration-controlled doses. <i>Therapeutic Drug Monitoring</i> , 2009 , 31, 451-6	3.2	5
71	Performance of the new mycophenolate assay based on IMPDH enzymatic activity for pharmacokinetic investigations and setup of Bayesian estimators in different populations of allograft recipients. <i>Therapeutic Drug Monitoring</i> , 2009 , 31, 443-50	3.2	11

70	Rheumatoid factor interference in a tacrolimus immunoassay. <i>Therapeutic Drug Monitoring</i> , 2009 , 31, 743-5	3.2	29
69	Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies. <i>Clinical Pharmacokinetics</i> , 2008 , 47, 277-84	6.2	36
68	Pitfalls and prevention strategies for liquid chromatography-tandem mass spectrometry in the selected reaction-monitoring mode for drug analysis. <i>Clinical Chemistry</i> , 2008 , 54, 1519-27	5.5	91
67	Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. <i>Hepatology</i> , 2008 , 47, 1453-61	11.2	75
66	Reply:. <i>Hepatology</i> , 2008 , 48, 693-694	11.2	
65	Identification of acepromazine in hair: an illustration of the difficulties encountered in investigating drug-facilitated crimes. <i>Journal of Forensic Sciences</i> , 2008 , 53, 755-9	1.8	20
64	Multicenter evaluation of a new inosine monophosphate dehydrogenase inhibition assay for quantification of total mycophenolic acid in plasma. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 428-33	3.2	26
63	Current role of LC-MS in therapeutic drug monitoring. <i>Analytical and Bioanalytical Chemistry</i> , 2007 , 388, 1327-49	4.4	92
62	Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. <i>Pharmacogenetics and Genomics</i> , 2007 , 17, 321-30	1.9	59
61	Metabolism of sirolimus in the presence or absence of cyclosporine by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5. <i>Drug Metabolism and Disposition</i> , 2007 , 35, 350-5	4	38
60	Pesticide contamination of workers in vineyards in France. <i>Journal of Exposure Science and Environmental Epidemiology</i> , 2006 , 16, 115-24	6.7	77
59	Screening of drugs and toxic compounds with liquid chromatography-linear ion trap tandem mass spectrometry. <i>Clinical Chemistry</i> , 2006 , 52, 1735-42	5.5	119
58	Liquid chromatography-tandem mass spectrometry for detection of low concentrations of 21 benzodiazepines, metabolites, and analogs in urine: method with forensic applications. <i>Clinical Chemistry</i> , 2006 , 52, 1346-55	5.5	56
57	Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients. <i>Clinical Pharmacokinetics</i> , 2006 , 45, 905-22	6.2	27
56	Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients. <i>Clinical Pharmacokinetics</i> , 2006 , 45, 1135-48	6.2	53
55	Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 138; author reply 139	3.2	1
54	Determination of mycophenolic acid plasma levels in renal transplant recipients co-administered sirolimus: comparison of an enzyme multiplied immunoassay technique (EMIT) and liquid chromatography-tandem mass spectrometry. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 274-7	3.2	39
53	Cyclosporine monitoring in renal transplant recipients with induction therapy: C2 levels in patients monitored on C0. <i>Fundamental and Clinical Pharmacology</i> , 2006 , 20, 91-6	3.1	3

52	A comparison of the effect of ciclosporin and sirolimus on the pharmacokinetics of mycophenolate in renal transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2006 , 62, 477-84	3.8	42
51	CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 80, 51-60	6.1	76
50	Post-mortem redistribution of three beta-blockers in the rabbit. <i>International Journal of Legal Medicine</i> , 2006 , 120, 226-32	3.1	27
49	A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil. <i>Clinical Pharmacokinetics</i> , 2005 , 44, 837-47	6.2	53
48	Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of Bayesian estimators using limited sampling strategies. <i>Clinical Pharmacokinetics</i> , 2005 , 44, 1317-28	6.2	42
47	Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. <i>Drug Metabolism and Disposition</i> , 2005 , 33, 139-46	4	226
46	Clinical application of population pharmacokinetic methods developed for immunosuppressive drugs. <i>Therapeutic Drug Monitoring</i> , 2005 , 27, 727-32	3.2	15
45	Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. <i>Therapeutic Drug Monitoring</i> , 2005 , 27, 354-61	3.2	84
44	LC-MS/MS systematic toxicological analysis: comparison of MS/MS spectra obtained with different instruments and settings. <i>Clinical Biochemistry</i> , 2005 , 38, 362-72	3.5	81
43	Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 78, 34-42	6.1	29
42	Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions. <i>American Journal of Transplantation</i> , 2005 , 5, 1477-82	8.7	33
41	In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. <i>Drug Metabolism and Disposition</i> , 2005 , 33, 689-95	4	112
40	Identification and quantitation of six non-depolarizing neuromuscular blocking agents by LC-MS in biological fluids. <i>Journal of Analytical Toxicology</i> , 2004 , 28, 105-10	2.9	24
39	Determination of three beta-blockers in biofluids and solid tissues by liquid chromatography-electrospray-mass spectrometry. <i>Journal of Analytical Toxicology</i> , 2004 , 28, 674-9	2.9	22
38	In vitro study of mycophenolic acid glucuronidation. <i>Drug Metabolism and Disposition</i> , 2004 , 32, 1524; author reply 1525	4	6
37	Low alfentanil target-concentrations improve hemodynamic and intubating conditions during induction with sevoflurane. <i>Canadian Journal of Anaesthesia</i> , 2004 , 51, 382-7	3	17
36	CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 75, 422-33	6.1	150
35	Ingestion of high-dose buprenorphine by a 4 year-old child. <i>Journal of Toxicology: Clinical Toxicology</i> , 2004 , 42, 993-5		11

34	Modelling ciclosporin double-peak absorption profiles in the early post-transplantation period. <i>Clinical Pharmacokinetics</i> , 2004 , 43, 1055-7	6.2	2
33	Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients. <i>Clinical Pharmacokinetics</i> , 2004 , 43, 253-66	6.2	88
32	Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. <i>Therapeutic Drug Monitoring</i> , 2004 , 26, 600-8	3.2	58
31	Comparison of liquid chromatography-tandem mass spectrometry with a commercial enzyme-multiplied immunoassay for the determination of plasma MPA in renal transplant recipients and consequences for therapeutic drug monitoring. <i>Therapeutic Drug Monitoring</i> , 2004 , 26, 609-19	3.2	73
30	Cyclosporine pharmacokinetics and dose monitoring after lung transplantation: comparison between cystic fibrosis and other conditions. <i>Transplantation</i> , 2003 , 76, 683-8	1.8	22
29	Evaluation of an improved general unknown screening procedure using liquid chromatography-electrospray-mass spectrometry by comparison with gas chromatography and high-performance liquid-chromatography--diode array detection. <i>Journal of the American Society for Mass Spectrometry</i> , 2003 , 14, 144-52	3.5	70
28	Mechanisms underlying postmortem redistribution of drugs: a review. <i>Journal of Analytical Toxicology</i> , 2003 , 27, 533-44	2.9	199
27	Influence of sampling-time error on cyclosporine measurements nominally at 2 hours after administration. <i>Clinical Chemistry</i> , 2003 , 49, 813-5	5.5	9
26	Analytical Aspects of Volatile Substance Abuse (VSA). <i>Journal of Forensic Sciences</i> , 2003 , 48, 2002376	1.8	11
25	Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy. <i>European Journal of Clinical Pharmacology</i> , 2002 , 57, 805-11	2.8	64
24	Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. <i>Fundamental and Clinical Pharmacology</i> , 2002 , 16, 253-62	3.1	83
23	An animal model for the study of chronopharmacokinetics of drugs and application to methotrexate and vinorelbine. <i>Toxicology and Applied Pharmacology</i> , 2002 , 183, 189-97	4.6	8
22	Is LC-MS suitable for a comprehensive screening of drugs and poisons in clinical toxicology?. <i>Therapeutic Drug Monitoring</i> , 2002 , 24, 125-33	3.2	60
21	Progress of liquid chromatography-mass spectrometry in clinical and forensic toxicology. <i>Therapeutic Drug Monitoring</i> , 2002 , 24, 255-76	3.2	105
20	Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants. <i>Clinical Pharmacokinetics</i> , 2002 , 41, 71-80	6.2	49
19	Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma. <i>Clinical Pharmacokinetics</i> , 2002 , 41, 1095-104	6.2	30
18	Sensitive and specific multiresidue methods for the determination of pesticides of various classes in clinical and forensic toxicology. <i>Forensic Science International</i> , 2001 , 121, 116-25	2.6	62
17	Application of a gamma model of absorption to oral cyclosporin. <i>Clinical Pharmacokinetics</i> , 2001 , 40, 375-82	6.2	48

16	Fatal Intoxications with Chloral Hydrate. <i>Journal of Forensic Sciences</i> , 2001 , 46, 15181J	1.8	3
15	The apoptosis-inducing toxin brefeldin A is taken up and secondarily released by neurons. <i>Neuroscience Research Communications</i> , 2000 , 27, 125-133		1
14	Adaptive control methods for the dose individualisation of anticancer agents. <i>Clinical Pharmacokinetics</i> , 2000 , 38, 315-53	6.2	43
13	A Non-fatal Case of Intoxication with Foxglove, Documented by Means of Liquid Chromatography-Electrospray-Mass Spectrometry. <i>Journal of Forensic Sciences</i> , 2000 , 45, 14845J	1.8	30
12	Relationship between psychotropic drugs and thyroid function: a review. <i>Toxicology and Applied Pharmacology</i> , 1998 , 149, 127-35	4.6	41
11	Thyroid accumulation and adverse effects of imipramine and desipramine in rats after long-term administration. <i>Pharmacology</i> , 1998 , 57, 242-8	2.3	8
10	Determination of buprenorphine and norbuprenorphine in whole blood by liquid chromatography-mass spectrometry. <i>Journal of Analytical Toxicology</i> , 1997 , 21, 160-5	2.9	56
9	Applications of liquid chromatography-mass spectrometry in analytical toxicology: a review. <i>Journal of Analytical Toxicology</i> , 1997 , 21, 116-26	2.9	75
8	Determination of LSD and N-demethyl-LSD in urine by liquid chromatography coupled to electrospray ionization mass spectrometry. <i>Biomedical Applications</i> , 1997 , 692, 329-35		23
7	Simultaneous determination of amphetamine and its analogs in human whole blood by gas chromatography-mass spectrometry. <i>Biomedical Applications</i> , 1997 , 700, 77-82		25
6	Buprenorphine withdrawal syndrome in a newborn. <i>Clinical Pharmacology and Therapeutics</i> , 1997 , 62, 569-71	6.1	68
5	Tungsten Determination in Biological Fluids, Hair and Nails by Plasma Emission Spectrometry in a Case of Severe Acute Intoxication in Man. <i>Journal of Forensic Sciences</i> , 1997 , 42, 14162J	1.8	24
4	Analytical findings in a suicide involving sodium azide. <i>Journal of Analytical Toxicology</i> , 1996 , 20, 134-8	2.9	33
3	Pharmacology of High-Dose Buprenorphine01-12		6
2	Case Study of Neonates Born to Mothers Undergoing Buprenorphine Maintenance Treatment125-136		5
1	Pharmacogenomics of Immunosuppressants70-97		